IOB - Delayed Quote USD
Teva Pharmaceutical Industries Limited (0LER.IL)
14.25
-0.10
(-0.70%)
At close: April 24 at 7:11:26 PM GMT+1
Research Analysis
Earnings Estimate
Currency in USD | Current Qtr. (Dec 2022) | Next Qtr. (Mar 2023) | Current Year (2022) | Next Year (2023) |
---|---|---|---|---|
No. of Analysts | 10 | 5 | 13 | 12 |
Avg. Estimate | 0.71 | 0.57 | 2.51 | 2.56 |
Low Estimate | 0.66 | 0.49 | 2.03 | 2.44 |
High Estimate | 0.78 | 0.63 | 2.6 | 2.68 |
Year Ago EPS | 0.77 | 0.55 | 2.58 | 2.51 |
Revenue Estimate
Currency in USD | Current Qtr. (Dec 2022) | Next Qtr. (Mar 2023) | Current Year (2022) | Next Year (2023) |
---|---|---|---|---|
No. of Analysts | 9 | 4 | 11 | 10 |
Avg. Estimate | 4.02B | 3.68B | 15.41B | 15.52B |
Low Estimate | 3.95B | 3.57B | 15.09B | 14.92B |
High Estimate | 4.12B | 3.83B | 16.73B | 15.92B |
Year Ago Sales | 4.1B | -- | 15.88B | 15.41B |
Sales Growth (year/est) | -1.90% | -- | -2.90% | 0.70% |
Earnings History
Currency in USD | 12/31/2021 | 3/31/2022 | 6/30/2022 | 9/30/2022 |
---|---|---|---|---|
EPS Est. | 0.73 | 0.56 | 0.56 | 0.62 |
EPS Actual | 0.77 | 0.55 | 0.68 | 0.59 |
Difference | 0.04 | -0.01 | 0.12 | -0.03 |
Surprise % | 5.50% | -1.80% | 21.40% | -4.80% |
EPS Trend
Currency in USD | Current Qtr. (Dec 2022) | Next Qtr. (Mar 2023) | Current Year (2022) | Next Year (2023) |
---|---|---|---|---|
Current Estimate | 0.71 | 0.57 | 2.51 | 2.56 |
7 Days Ago | 0.7 | 0.57 | 2.51 | 2.55 |
30 Days Ago | 0.71 | 0.56 | 2.5 | 2.55 |
60 Days Ago | 0.73 | 0.55 | 2.44 | 2.58 |
90 Days Ago | 0.73 | 0.55 | 2.44 | 2.58 |
EPS Revisions
Currency in USD | Current Qtr. (Dec 2022) | Next Qtr. (Mar 2023) | Current Year (2022) | Next Year (2023) |
---|---|---|---|---|
Up Last 7 Days | 1 | -- | 1 | 1 |
Up Last 30 Days | 1 | 1 | 1 | 1 |
Down Last 7 Days | -- | -- | -- | -- |
Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
Current Qtr. | Next Qtr. | Current Year | Next Year | |
---|---|---|---|---|
0LER.IL | -7.80% | 3.60% | -2.70% | 2.00% |
S&P 500 | 6.94% | 4.52% | 8.32% | 14.18% |
Upgrades & Downgrades
Maintains | B of A Securities: Buy to Buy | 3/6/2025 |
Maintains | UBS: Buy to Buy | 1/30/2025 |
Maintains | Barclays: Overweight to Overweight | 1/30/2025 |
Maintains | UBS: Buy to Buy | 1/23/2025 |
Maintains | Piper Sandler: Overweight to Overweight | 1/17/2025 |
Maintains | Barclays: Overweight to Overweight | 12/18/2024 |